Anemia and Bone Marrow Suppression after Intra-Arterial Chemotherapy in Children with Retinoblastoma
DOI:
https://doi.org/10.53350/pjmhs02025194.4Keywords:
Retinoblastoma, Intra-arterial Chemotherapy (IAC), Anemia, Bone Marrow Suppression, Pediatric Oncology.Abstract
Background: Intra-arterial chemotherapy (IAC) has become a vital treatment approach for retinoblastoma, particularly in cases where other therapies have failed.
Objective: This study investigates the incidence, severity, and factors influencing anemia and bone marrow suppression in children with retinoblastoma undergoing IAC.
Methods: This retrospective study was conducted at Pediatrics Department, Swat Medical College & Swat Medical Complex Teaching Hospital Saidu Sharif Swat during January 2024 to August 2024. A total of 185 pediatric patients who underwent IAC treatment for retinoblastoma were included in this study. Patients aged 0 to 18 years who had received at least one cycle of IAC as part of their treatment regimen for retinoblastoma were included in the study. Patients who had incomplete medical records or were lost to follow-up were excluded from the study.
Results: The incidence of anemia increased from 10% before IAC to 65% after treatment. Bone marrow suppression was observed in 55% of patients, with severe neutropenia and thrombocytopenia occurring in 15% and 10%, respectively. The number of IAC cycles (≥5) and the dose of melphalan were significant predictors of anemia and bone marrow suppression severity (p < 0.01). Advanced-stage disease was also associated with a higher risk of severe hematologic toxicity (p < 0.05). Supportive care interventions, such as blood transfusions and granulocyte colony-stimulating factor (G-CSF), were effective in managing these complications.
Conclusion: Anemia and bone marrow suppression are common complications in children with retinoblastoma undergoing IAC.
References
Zeng C, Han M, Fan J, He X, Jia R, Li L, Wen X, Song X, Hou L. Anemia and Bone Marrow Suppression After Intra-Arterial Chemotherapy in Children With Retinoblastoma: A Retrospective Analysis. Front Oncol. 2022 Jul 25;12:848877. doi: 10.3389/fonc.2022.848877. PMID: 35957866; PMCID: PMC9359439.
Sanati-Mehrizy A, Ghosh T, Peterson E, Starke RM, Harbour JW, Corrales-Medina FF. Hematologic Complications Associated With Intra-arterial Chemotherapy for Retinoblastoma Treatment: A Single Institution Experience. J Pediatr Hematol Oncol. 2022 May 1;44(4):181-185. doi: 10.1097/MPH.0000000000002451. Epub 2022 Mar 25. PMID: 35446803.
Chen Q, Zhang B, Dong Y, Mo X, Zhang L, Xia J, et al. Evaluating Primary Intra-Arterial Chemotherapy Versus Intravenous Plus Intra-Arterial Chemotherapy for Advanced Intraocular Retinoblastoma. Cancer Chemother Pharmacol. 2020;85(4):723–30. doi: 10.1007/s00280-020-04036-w.
Daniels AB, Patel SN, Milam RW, Kohanim S, Friedman DL, Koyama T. Effect of Intravenous Chemotherapy Regimen on Globe Salvage Success Rates for Retinoblastoma Based on Disease Class- A Meta-Analysis. Cancers (Basel). 2021;13(9):2216. doi: 10.3390/cancers13092216.
Sweid A, Jabbour P. Intra-Arterial Chemotherapy for Retinoblastoma: Transradial and Transfemoral Approach. J Neurointerv Surg. 2020;12(8):828. doi: 10.1136/neurintsurg-2019- 015627.
Ravindran K, Dalvin LA, Pulido JS, Brinjikji W. Intra-Arterial Chemotherapy for Retinoblastoma: An Updated Systematic Review and Meta-Analysis. J Neurointerv Surg. 2019;11(11):1266–72. doi: 10.1136/neurintsurg-2019-014909.
Oporto JI, Zuniga P, Ossandon D, Zanolli M, Perez V, Lopez JP, et al. Intra-Arterial Chemotherapy for Retinoblastoma Treatment in Chile: Experience and Results 2013-2020. Arch Soc Esp Oftalmol (Engl Ed). 2021;96(5):288–92. doi: 10.1016/j.oftale.2020.10.003.
Zhou M, Wen X, Jia S, Han Y, He X, Han M, et al. Risk Factors for Ophthalmic Artery Stenosis and Occlusion in Patients With Retinoblastoma Treated With Intra-Arterial Chemotherapy. Br J Ophthalmol. 2021. doi: 10.1136/bjophthalmol-2021-319118.
Selzer EB, Welch RJ, Jabbour P, Leahey AM, Shields CL. Management of retinoblastoma in older children (>5 years) using intra-arterial chemotherapy: Comparison of outcomes to prechemotherapy and intravenous chemotherapy eras. Indian J Ophthalmol. 2019 Dec;67(12):2005-2011. doi: 10.4103/ijo.IJO_642_19. PMID: 31755439; PMCID: PMC6896522.
Shields CL, Kaliki S, Al-Dahmash S, Rojanaporn D, Leahey A, Griffin G, et al. Management of advanced retinoblastoma with intravenous chemotherapy then intra-arterial chemotherapy as alternative to enucleation. Retina. 2013;33:2103–9.
Shields CL, Manjandavida FP, Lally SE, Pieretti G, Arepalli SA, Caywood EH, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes. Ophthalmology. 2014;121:1453–60.
Grigorovski N, Lucena E, Mattosinho C, Parareda A, Ferman S, Catalá J, et al. Use of intra-arterial chemotherapy for retinoblastoma: Results of a survey. Int J Ophthalmol. 2014;7:726–30.
Dalvin LA, Ancona-Lezama D, Lucio-Alvarez JA, Masoomian B, Jabbour P, Shields CL, et al. Ophthalmic vascular events following primary unilateral IAC for retinoblastoma in early and recent eras. A consecutive comparative analysis. Ophthalmology. 2018;125:1803–11.
Ancona-Lezama D, Dalvin LA, Lucio-Alvarez JA, Jabbour P, Shields CL. Ophthalmic vascular events after intra-arterial chemotherapy for retinoblastoma. Real-world comparison between primary and secondary treatments. Retina. 2018 Sep 7; [Epub ahead of print]. doi: 10.1097/IAE.0000000000002315.
Abramson DH, Shields CL, Jabbour P, Teixeira LF, Munier FL, Puccinelli F, et al. Metastatic deaths in retinoblastoma patients treated with intraarterial chemotherapy (ophthalmic artery chemosurgery) worldwide. Int J Retina Vitreous. 2017:3. doi: 10.1186/s40942-017-0093-8.
Shanmugam PM. Commentary: The shift to intra-arterial chemotherapy - Relevance in Indian context. Indian J Ophthalmol. 2019 Dec;67(12):2011-2012. doi: 10.4103/ijo.IJO_1193_19. PMID:31755440; PMCID: PMC6896541.
Selzer EB, Welch RJ, Jabbour P, Leahey AM, Shields CL. Management of retinoblastoma in older children (>5 years) using intra-arterial chemotherapy: Comparison of outcomes to prechemotherapy and intravenous chemotherapy eras. Indian J Ophthalmol. 2019;67:2005–11
Francis JH, Roosipu N, Levin AM, Brodie S, Dunkel IJ, Gobin YP, et al. Current treatment of bilateral retinoblastoma: The impact of intraarterial and intravitreous chemotherapy. Neoplasia. 2018;20:757–63
Munier FL, Mosimann P, Puccinelli F, Gaillard MC, Stathopoulos C, Houghton S, et al. First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: Evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment. Br J Ophthalmol. 2017;101:1086– 93
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2025 SIRAJ NABI, SAYED ALI, AMIR ZEB KHAN, MARIUM NADEEM KHAN, GEETA KUMARI
This work is licensed under a Creative Commons Attribution 4.0 International License.
